
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
Click to see a preview of what to expect this week.
Some of the content the staff at Dermatology Times® will be publishing this week includes:
Content from the December Issue;
Coverage on roflumilast cream and other trending topics;
Exclusive video interviews with KOLs;
Plus more!






